Claris Lifesciences (Claris) has reached a settlement and license agreement, ending all pending litigation with Fresenius Kabi USA, Inc with reference to the alleged infringement of a patent relating to Propofol for Injection, 10 mg/ml, which is a generic version of DIPRIVAN.
Under the terms of the settlement and license agreement, Claris and Claris Lifesciences Inc (USA) has been granted approval to sell its generic version of Propofol for Injection beginning October 15, 2016, prior to the June 1, 2025 expiry of the patent that formed the basis of the litigation. According to IMS health data as of June 2014, Propofol Injection had an annual market size of approximately US$ 251 million in the USA.
Claris manufactures and markets products across multiple delivery systems, markets, and therapeutic segments including anesthesia, blood products, anti-infectives, and plasma volume expanders. A significant majority of these products are generic drugs that are capable of being directly injected into the human body, which are predominantly used in the treatment of critical illnesses.
